Virax Biolabs Group Ltd (VRAX) Liabilities and Shareholders Equity (2021 - 2025)

Virax Biolabs (VRAX) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $6.4 million in Q1 2025.

• In Q1 2025, Liabilities and Shareholders Equity rose 17.19% year-over-year to $6.4 million; the TTM figure through Mar 2025 stood at $21.7 million (up 41.65% YoY), while the FY2025 annual figure was $6.4 million, up 17.19% from the prior year.
• Liabilities and Shareholders Equity climbed to $6.4 million in Q1 2025, from $5.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $9.8 million in Q1 2023 and bottomed at $39621.0 in Q1 2021.
• A 4-year average of $5.4 million and a median of $6.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity sank 44.11% — and 2025, when it grew 17.19%.
• Year by year, Liabilities and Shareholders Equity stood at $39621.0 in 2021, then jumped by 24665.69% to $9.8 million in 2023, then slumped by 44.11% to $5.5 million in 2024, then increased by 17.19% to $6.4 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $6.4 million (Q1 2025), $5.5 million (Q1 2024), and $9.8 million (Q1 2023), per Business Quant data.

Peer Comparison